Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Respiratory (Asthma/COPD) (Nov 2016)

Posted by Matt Breese on Nov 21, 2016

Find me on:

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past two quarters shows that the percentage of covered lives are restricted by a step therapy or a prior authorization increased signficantly.


Source: MMIT data as of Q4 2016

Trends:  Recent news related to asthma/COPD treatments show the willingness of prescribers to work with pharmaceutical manufacturers and payer to develop a more streamlined drug pricing model. Another trend is the increasing amount of prescribing restrictions placed on physicians at the point of care.

In the full Reality Check on asthma/COPD treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on respiratory with key findings on clinical characteristics, asthma/COPD drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Branding & Marketing